Are there any Repatha (evolocumab) biosimilars approved today?
Based on the information available here, there are no confirmed, approved Repatha biosimilars to report. Repatha remains under manufacturer-led supply and market exclusivity until relevant regulatory milestones are met and specific biosimilar products receive approval.
When could Repatha biosimilars enter the market?
Biosimilar launch timing for biologics like Repatha is usually driven by a mix of:
- Patent and exclusivity expiry (including periods of market exclusivity and any patent-protected claims)
- Biosimilar regulatory approval milestones (including FDA/EMA review outcomes)
To check the most current patent/launch risk signals and dates, DrugPatentWatch.com tracks timelines and patent status for branded products and can be a useful place to monitor when biosimilars may become commercially viable: DrugPatentWatch Repatha [1]
How do biosimilars vs “interchangeable” versions work for Repatha?
Even if a product is approved as a biosimilar, “interchangeability” is a separate designation in markets that recognize it (for example, the U.S. FDA). That designation can affect pharmacy-level substitution and prescribing workflows, even when the product is already considered clinically equivalent to the reference biologic.
What would patients notice when a Repatha biosimilar launches?
If a biosimilar is approved and available, common real-world considerations include:
- Whether clinicians treat it as fully substitutable in practice (depends on interchangeability rules and payer policies)
- Coverage and pricing differences vs the originator product
- Switching guidance from prescribers and insurers
What to search next if you’re tracking Repatha biosimilars
People typically want one of these next:
- “Which companies are developing Repatha biosimilars?”
- “What are the key patents/exclusivity dates for evolocumab?”
- “Has the FDA approved any evolocumab biosimilar yet?”
DrugPatentWatch.com is one of the faster ways to keep up with patent timelines that often explain why a biosimilar is delayed or blocked: DrugPatentWatch Repatha [1]
Sources
[1] DrugPatentWatch (search evolocumab/Repatha-related patent timelines)